Spyre Therapeutics, Inc. is a biotech company developing new medicines.
Spyre Therapeutics, Inc. (SYRE) is expected to report earnings on Tuesday, November 3, 2026, after the close. Estimated release time 16:05 ET. Consensus EPS estimate is $-0.80.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-04 | FY2026 Q2 | $-0.76 | $-0.36 | +52.6% | $0 |
| 2026-05-05 | FY2026 Q1 | $-0.66 | $-0.74 | -12.1% | $0 |
| 2026-02-19 | FY2025 Q4 | $-0.66 | $-0.70 | -6.1% | $90.49M |
| 2025-11-04 | FY2025 Q3 | $-0.76 | $-0.15 | +80.3% | $0 |
| 2025-08-05 | FY2025 Q2 | $-0.73 | $-0.60 | +17.8% | $0 |
| 2025-05-08 | FY2025 Q1 | $-0.84 | $-0.13 | +84.5% | $0 |
| 2025-02-27 | FY2024 Q4 | $-0.89 | $-0.15 | +83.1% | $0 |
| 2024-11-18 | FY2024 Q3 | — | $-1.36 | — | $0 |
SYRE has beaten consensus EPS in 5 of its last 8 reported quarters.
See SYRE on the live calendar →